Plus   Neg

Liquidia: FDA Issues CRL For LIQ861; CRL Focuses On Drug CMC, Device Biocompatibility Information

Liquidia Technologies, Inc., a unit of Liquidia Corp. (LQDA), has received a complete response letter from the FDA for the New Drug Application for LIQ861 (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension. The FDA stated that it is unable to approve the NDA at this time. The CRL identified the need for additional information and clarification on chemistry, manufacturing and controls data pertaining to the drug product and device biocompatibility. The CRL did not cite the need to conduct further clinical studies.

Liquidia said the company does not believe that the items raised in the CRL will be a barrier to the ultimate approval of LIQ861. Liquidia believes the company can address the items raised in the CRL without delaying the otherwise projected launch timing of LIQ861 in the second half of 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
Follow RTT